PD L1 News and Research

RSS

New drug combination shows promise for patients with non-small cell lung cancer

Lung cancer is the most common cause of cancer-related death in the United States resulting in more than 158,000 deaths each year. With a 5-year survival rate at only 18 percent, the development of new and improved treatment options is needed.

18 Feb 2016

Quest Diagnostics to offer in vitro diagnostic test for use in detection of PD-L1 expression for melanoma

Quest Diagnostics, the world’s leading provider of diagnostic information services, today announced it will offer clinical laboratory testing using the PD-L1 IHC 28-8 pharmDx qualitative test from Dako, an Agilent Technologies company.

From Quest Diagnostics 27 Jan 2016

PD-L1 inhibition well-tolerated, active in metastatic RCC

The programmed death-ligand 1 inhibitor atezolizumab has a favourable toxicity profile and shows anti-tumour activity in previously treated patients with metastatic renal cell carcinoma, according to phase Ia trial findings.

19 Jan 2016

Study shows more patients with advanced NSCLC may benefit from pembrolizumab

More patients with advanced non-small-cell lung cancer (NSCLC) could benefit from pembrolizumab, says Professor Roy Herbst, Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven, presenting promising results from the pivotal phase 2/3 KEYNOTE-010 trial at the first ESMO Asia Congress in Singapore), in conjunction with a publication in The Lancet.

22 Dec 2015

MD Anderson study reveals MDSCs as likely target for developing prostate cancer treatments

Immune suppressor cells called MDSCs (myeloid-derived suppressor cells) may be important in developing treatments for advanced prostate cancer, according to a study at The University of Texas MD Anderson Cancer Center.

22 Dec 2015

Immunotherapy more effective than chemotherapy in treating patients with advanced lung cancer

A new study has found immunotherapy to be more effective than chemotherapy in treating most previously treated patients with advanced lung cancer, and demonstrated effectiveness in a wider population of people than previously known to benefit from the therapy.

22 Dec 2015

Novel strategies on the way for difficult-to-treat head and neck cancer

Novel strategies are on the way for difficult-to-treat and advanced head and neck cancer, the most heterogeneous group of malignancies which are generally associated with poor survival, and encouraging results have been presented at the first ESMO Asia 2015 Congress in Singapore.

17 Dec 2015

Lilly, Merck announce another immuno-oncology collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced another immuno-oncology collaboration that will evaluate abemaciclib (LY2835219), Lilly's cyclin-dependent kinase (CDK) 4 and 6 inhibitor, and Merck's KEYTRUDA (pembrolizumab) in a Phase I study across multiple tumor types.

10 Dec 2015

Opdivo (nivolumab) approved to treat patients with advanced renal cell carcinoma

The U.S. Food and Drug Administration today approved Opdivo (nivolumab) to treat patients with advanced (metastatic) renal cell carcinoma, a form of kidney cancer, who have received a certain type of prior therapy.

23 Nov 2015

Lilly, Merck expand oncology clinical trial collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly's ALIMTA (pemetrexed for injection) and Merck's KEYTRUDA (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC).

19 Nov 2015

Viralytics enters into clinical trial collaboration agreement with MSD

Viralytics Limited announced today that it has entered into a clinical trial collaboration agreement through subsidiaries of Merck & Co., Inc., Kenilworth, New Jersey, U.S.A. (known as MSD outside the United States and Canada) to evaluate the combination of Viralytics' investigational cancer immunotherapy CAVATAK, with MSD's KEYTRUDA, an anti-PD-1 (programmed death receptor-1) therapy.

6 Nov 2015

Specific gut bacteria can improve cancer immunotherapy, show studies

By introducing a particular strain of bacteria into the digestive tracts of mice with melanoma, researchers at the University of Chicago were able to boost the ability of the animal's immune systems to attack tumor cells. T

6 Nov 2015

New study identifies molecular mechanism that prevents immunotherapy drugs from killing off cancer

Immunotherapy treatments have proven wildly successful in treating some patients with cancer. But despite this success, the majority of patients do not respond to the treatments.

27 Oct 2015

Nivolumab vs docetaxel updated results for nonsquamous, squamous NSCLC

Follow-up results from two trials of the programmed death 1 receptor inhibitor nivolumab versus docetaxel in patients with advanced non-small cell lung cancer were reported at a proffered paper session held at the European Cancer Congress in Vienna, Austria.

23 Oct 2015

Lilly expands existing immuno-oncology collaboration with AstraZeneca

Eli Lilly and Company today announced an extension to their existing immuno-oncology collaboration exploring novel combination therapies for the treatment of patients with solid tumors.

22 Oct 2015

Quest Diagnostics provides Dako’s PD-L1 complementary diagnostic test for non-squamous non-small cell carcinoma

Quest Diagnostics, the world's leading provider of diagnostic information services, today announced that it now provides clinical laboratory testing using the PD-L1 IHC 28-8 pharmDx immunohistochemistry test, available through Dako, an Agilent Technologies company.

From Quest Diagnostics 13 Oct 2015

FDA approves Opdivo to treat patients with advanced non-small cell lung cancer

The U.S. Food and Drug Administration today approved Opdivo (nivolumab) to treat patients with advanced (metastatic) non-small cell lung cancer whose disease progressed during or after platinum-based chemotherapy.

11 Oct 2015

IASLC commends pembrolizumab drug approval for cutting-edge lung cancer treatment

The International Association for the Study of Lung Cancer (IASLC) says the move by the U.S. Food and Drug Administration (FDA) to grant accelerated approval for a cutting-edge lung cancer treatment is a positive step forward that may help many patients improve their survival.

9 Oct 2015

FDA grants accelerated approval for Keytruda to treat patients with advanced NSCLC

The U.S. Food and Drug Administration today granted accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non-small cell lung cancer (NSCLC) whose disease has progressed after other treatments and with tumors that express a protein called PD-L1. Keytruda is approved for use with a companion diagnostic, the PD-L1 IHC 22C3 pharmDx test, the first test designed to detect PD-L1 expression in non-small cell lung tumors.

9 Oct 2015

Quest Diagnostics provides PD-L1 IHC 22C3 PharmDx test service for NSCLC patients

Quest Diagnostics, the world’s leading provider of diagnostic information services, today announced that it will provide clinical laboratory testing using the PD-L1 IHC 22C3 PharmDx immunohistochemistry companion diagnostic.

From Quest Diagnostics 7 Oct 2015

PD L1 News and Research

New drug combination shows promise for patients with non-small cell lung cancer

Quest Diagnostics to offer in vitro diagnostic test for use in detection of PD-L1 expression for melanoma

PD-L1 inhibition well-tolerated, active in metastatic RCC

Study shows more patients with advanced NSCLC may benefit from pembrolizumab

MD Anderson study reveals MDSCs as likely target for developing prostate cancer treatments

Immunotherapy more effective than chemotherapy in treating patients with advanced lung cancer

Novel strategies on the way for difficult-to-treat head and neck cancer

Lilly, Merck announce another immuno-oncology collaboration

Opdivo (nivolumab) approved to treat patients with advanced renal cell carcinoma

Lilly, Merck expand oncology clinical trial collaboration

Viralytics enters into clinical trial collaboration agreement with MSD

Specific gut bacteria can improve cancer immunotherapy, show studies

New study identifies molecular mechanism that prevents immunotherapy drugs from killing off cancer

Nivolumab vs docetaxel updated results for nonsquamous, squamous NSCLC

Lilly expands existing immuno-oncology collaboration with AstraZeneca

Quest Diagnostics provides Dako’s PD-L1 complementary diagnostic test for non-squamous non-small cell carcinoma

FDA approves Opdivo to treat patients with advanced non-small cell lung cancer

IASLC commends pembrolizumab drug approval for cutting-edge lung cancer treatment

FDA grants accelerated approval for Keytruda to treat patients with advanced NSCLC

Quest Diagnostics provides PD-L1 IHC 22C3 PharmDx test service for NSCLC patients

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News